Gland Pharma Limited (BOM: 543245)
India
· Delayed Price · Currency is INR 1,769.75
-6.05 (-0.34%)
At close: Dec 20, 2024
Gland Pharma Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2017 |
| Net Income | 6,916 | 7,725 | 7,810 | 12,117 | 9,970 | 7,729 | Upgrade
|
| Depreciation & Amortization | 3,837 | 3,446 | 1,467 | 1,103 | 987.8 | 945.87 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.23 | -2.49 | 0.81 | 1.78 | -0.24 | -173.93 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | 63.32 | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -10.58 | -3.48 | -28.48 | -44.89 | - | - | Upgrade
|
| Stock-Based Compensation | - | - | - | 46.21 | 155.34 | 164.84 | Upgrade
|
| Provision & Write-off of Bad Debts | 110.84 | 214.21 | 22.04 | 41.27 | -25.85 | 59.31 | Upgrade
|
| Other Operating Activities | -1,287 | -878.54 | -1,516 | -1,426 | -679.8 | -915.9 | Upgrade
|
| Change in Accounts Receivable | -1,089 | -3,250 | 1,440 | -4,196 | -602.01 | -805.17 | Upgrade
|
| Change in Inventory | 5,316 | 6,661 | -7,596 | 895.01 | -5,189 | 1,556 | Upgrade
|
| Change in Accounts Payable | -161.85 | -3,789 | 1,210 | 659.19 | 1,384 | -2,147 | Upgrade
|
| Change in Other Net Operating Assets | -1,445 | -154.51 | 767.19 | -1,289 | 48.9 | 596.51 | Upgrade
|
| Operating Cash Flow | 12,187 | 9,968 | 3,640 | 7,908 | 6,049 | 7,009 | Upgrade
|
| Operating Cash Flow Growth | 212.37% | 173.87% | -53.97% | 30.72% | -13.70% | 278.36% | Upgrade
|
| Capital Expenditures | -3,865 | -3,899 | -2,209 | -5,113 | -2,288 | -1,947 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.69 | 7.67 | 1.4 | 3.99 | 4.3 | 238.86 | Upgrade
|
| Cash Acquisitions | - | -10,218 | - | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -127.28 | -83.26 | -21.9 | -107.92 | - | - | Upgrade
|
| Investment in Securities | 17,830 | -4,747 | 12,706 | -6,117 | -13,576 | -6,387 | Upgrade
|
| Other Investing Activities | 1,216 | 1,371 | 1,606 | 1,308 | 619.37 | 434.47 | Upgrade
|
| Investing Cash Flow | 15,055 | -17,569 | 12,082 | -10,026 | -15,240 | -7,661 | Upgrade
|
| Long-Term Debt Issued | - | 210.28 | - | - | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -7,954 | -2.9 | -2.52 | -10.16 | -6.2 | Upgrade
|
| Total Debt Repaid | -804.12 | -7,954 | -2.9 | -2.52 | -10.16 | -6.2 | Upgrade
|
| Net Debt Issued (Repaid) | -457.98 | -7,743 | -2.9 | -2.52 | -10.16 | -6.2 | Upgrade
|
| Issuance of Common Stock | 26.99 | 5.26 | 214.96 | 385.52 | 12,418 | - | Upgrade
|
| Other Financing Activities | -285.06 | -256.11 | -62.87 | -34.02 | -23.31 | -62.51 | Upgrade
|
| Financing Cash Flow | -4,011 | -7,994 | 149.19 | 348.98 | 12,385 | -68.71 | Upgrade
|
| Foreign Exchange Rate Adjustments | 162.53 | 77.23 | 30 | 33.11 | 35.77 | 51.09 | Upgrade
|
| Net Cash Flow | 23,393 | -15,518 | 15,901 | -1,736 | 3,230 | -669.05 | Upgrade
|
| Free Cash Flow | 8,322 | 6,069 | 1,430 | 2,794 | 3,762 | 5,063 | Upgrade
|
| Free Cash Flow Growth | 818.83% | 324.27% | -48.81% | -25.71% | -25.70% | 922.55% | Upgrade
|
| Free Cash Flow Margin | 14.13% | 10.71% | 3.95% | 6.35% | 10.86% | 19.23% | Upgrade
|
| Free Cash Flow Per Share | 50.52 | 36.84 | 8.69 | 16.98 | 23.77 | 32.67 | Upgrade
|
| Cash Interest Paid | 285.06 | 256.11 | 62.87 | 34.02 | 23.31 | 62.51 | Upgrade
|
| Cash Income Tax Paid | 3,200 | 3,061 | 3,109 | 4,065 | 3,114 | 2,441 | Upgrade
|
| Levered Free Cash Flow | 7,819 | 4,211 | 875.11 | 493.54 | 2,037 | 3,791 | Upgrade
|
| Unlevered Free Cash Flow | 7,960 | 4,347 | 914.4 | 514.8 | 2,055 | 3,830 | Upgrade
|
| Change in Net Working Capital | -2,535 | 1,294 | 3,850 | 4,163 | 4,322 | 714.99 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.